Australia markets closed

Viridian Therapeutics, Inc. (1S1.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
12.00+0.50 (+4.35%)
At close: 08:06AM CEST
Show:
Balance sheet
Cash flow
Annual

Income statement

Currency in USD. All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Total revenue
288
314
1,772
2,963
1,050
Operating expenses
Research development
149,969
159,765
100,894
56,886
28,304
Selling general and administrative
88,193
94,999
35,182
25,805
13,265
Total operating expenses
238,162
254,764
136,076
82,691
41,569
Operating income or loss
-237,874
-254,450
-134,304
-79,728
-40,519
Interest expense
2,269
1,847
486
3
508
Total other income/expenses net
-
-
-
-
-69,861
Income before tax
-218,125
-237,734
-129,874
-79,413
-110,715
Income from continuing operations
-218,125
-237,734
-129,874
-79,413
-110,715
Net income
-218,125
-237,734
-129,874
-79,413
-110,715
Net income available to common shareholders
-218,125
-237,734
-129,874
-79,413
-110,715
Basic EPS
-5.14
-5.31
-4.05
-6.66
-31.13
Diluted EPS
-5.14
-5.31
-4.05
-6.66
-31.13
Basic average shares
42,452
44,755
32,087
11,919
3,557
Diluted average shares
42,452
44,755
32,087
11,919
3,557